Janus kinase inhibitor cycling may be more effective than switching to bDMARDs among patients with RA who had an inadequate response to initial JAK inhibitor therapy.

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

About the ROCKET Phase 3 Program ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

A study from the FIRST registry finds that rheumatoid arthritis patients with an inadequate response to JAK inhibitors may ...

As per their name, entry/attachment inhibitors work by blocking the virus's ability to attach to or enter healthy host cells. They do so by binding to different receptors on the surface of the host ...

Angiotensin-converting enzyme (ACE) inhibitors are oral medications that lower blood pressure. They are used to treat a variety of heart-related conditions including high blood pressure, coronary ...